Clinical trials: Erosive Esophagitis
Erosive Esophagitis
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
To evaluate the healing rate and safety of Lafutidine in erosive esophagitis
- Trial name
- NCT01499368
- Testing
- Lafutidine, Famotidine, Omeprazole
- Volunteers
- 495 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Erosive Esophagitis
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis
The purpose of this study is to confirm the efficacy of TAK-438, once daily (QD), compared to lansoprazole for the maintenance treatment of healed erosive esophagitis and to determine the clinical dose.
- Trial name
- NCT01459367
- Testing
- TAK-438, Lansoprazole
- Where
- 37 sites in Japan
- Volunteers
- 607 people
- Sponsor
- Takeda
Erosive Esophagitis, GERD
Efficacy Study of Ilaprazole to Treat Erosive Esophgitis
This study compared Ilaprazole 20mg with lansoprazole 30mg for the healing of erosive esophagitis and resolution of heartburn.
- Trial name
- NCT01509261
- Testing
- Ilaprazole, Lansoprazole
- Where
- 19 sites in South Korea
- Volunteers
- 292 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Erosive Esophagitis
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis
This is a comparative study of vonoprazan (TAK-438) (10 mg or 20 mg) in participants in whom endoscopic healing of erosive esophagitis has been confirmed with vonoprazan or adequate treatment with a proton pump inhibitor (PPI)…
- Trial name
- NCT02388737
- Testing
- Vonoprazan, Lansoprazole
- Where
- 72 sites in China, Malaysia and 2 more
- Volunteers
- 703 people
- Sponsor
- Takeda
Reflux Esophagitis
Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis
This open label, non-interventional study is to compare the efficacy of Omepral® tablet and any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various type of acid reflux related symptoms in…
- Trial name
- OMAREE (NCT00859287)
- Volunteers
- 10,703 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
The purpose of this study is to confirm the efficacy of CJ-12420, Once daily (QD), compared to esomeprazole in patients with erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.
- Trial name
- NCT03006874
- Testing
- CJ-12420 100mg QD, Esomeprazole 40mg, CJ-12420 50mg QD
- Where
- South Korea
- Volunteers
- 302 people
- Sponsor
- HK inno.N Corporation
Erosive Esophagitis
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach.
- Trial name
- NCT02615184
- Testing
- Dexlansoprazole
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 24 people
- Sponsor
- Takeda
GERD
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to evaluate whether there is a difference in proportion of patients with resolution of heartburn and other symptoms related to gastroesophageal reflux disease (GERD) after four weeks of treatment with…
- Trial name
- NCT00242736
- Testing
- Esomeprazole
- Where
- 25 sites in United States
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
GERD
Impact of GERD on Daily Life (NIS)
The aim of this study is to gather epidemiological data in a population of GERD patients in primary care with a history of erosive esophagitis (less than or equal to 3 years).
- Trial name
- Alegria (NCT00545883)
- Where
- 112 sites in Belgium
- Volunteers
- 2,001 people
- Sponsor
- AstraZeneca
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically…
- Trial name
- NCT00251719
- Testing
- Dexlansoprazole MR, Lansoprazole
- Where
- 144 sites in United States, Australia and 14 more
- Volunteers
- 2,054 people
- Sponsor
- Takeda
Erosive Esophagitis
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008
This will be a Phase I, randomized, double-blind, positive- and placebo-controlled study to evaluate the safety, tolerability, and PK/PD of multiple oral doses of H008 in healthy adult subjects.
- Trial name
- NCT05050188
- Testing
- H008, Lansoprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu Carephar Pharmaceutical Co., Ltd.
Esophagitis, Reflux
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
The purpose of this study was to compare the pharmacodynamics of intravenous (IV) lansoprazole to oral lansoprazole capsules, once daily (QD), in participants with erosive esophagitis.
- Trial name
- NCT00175045
- Testing
- Lansoprazole
- Volunteers
- 68 people
- Sponsor
- Takeda
Erosive Esophagitis
Treatment Effect According to Timing of Administration of DWP14012 40 mg
The primary objective of this study is to establish noninferiority of efficacy of DWP14012 (40 mg once daily) based on Timing of Administration.
- Trial name
- NCT04613895
- Testing
- DWP14012
- Where
- South Korea
- Volunteers
- 186 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Erosive Esophagitis
A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis
The purpose of this study is to evaluate the acid-inhibitory and dose-response efficacy of TAK-438 (20 mg, 40 mg) in patients with PPI-resistant erosive esophagitis.
- Trial name
- NCT01630746
- Testing
- TAK-438
- Where
- 11 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Takeda
Esophagitis, Reflux
Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis
STU-Na belongs to the proton pump inhibitors (PPI), a group of drugs that reduce gastric acidity. PPI are used to treat acid related diseases like erosive or ulcerative esophagitis.
- Trial name
- NCT00282555
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- 17 sites in Canada
- Volunteers
- 450 people
- Sponsor
- STEBA France
Erosive Esophagitis(EE), Gastroesophageal Reflux Disease (GERD)
TAK-438 - Safety, Blood Levels & Effects of Repeated Doses
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 in healthy, non-Japanese men male subjects following a randomized, double blind, placebo controlled, sequential panel…
- Trial name
- TAK-438_107 (NCT02141711)
- Testing
- TAK-438
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Takeda
Erosive Esophagitis
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)
The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.
- Trial name
- NCT03736369
- Testing
- DWP14012 40mg, Esomeprazole 40mg
- Where
- South Korea
- Volunteers
- 263 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Erosive Esophagitis
Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety
The purpose of this study is exploratorily evaluate the effect on gastric mucosal tissue and the safety of long-term administration (260 weeks: 5 years) of vonoprazan 10 mg or 20 mg in patients receiving maintenance treatment…
- Trial name
- NCT02679508
- Testing
- Vonoprazan, Lansoprazole
- Where
- 36 sites in Japan
- Volunteers
- 208 people
- Sponsor
- Takeda
Esophagitis, Reflux
To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis
The purpose of this study is to evaluate the efficacy and safety of Z-215 (10 mg, 20 mg, 40 mg) , compared with Rabeprazole Sodium 10mg in patients with erosive esophagitis of Grade A to D as defined by the LA classification…
- Trial name
- NCT02463643
- Testing
- Z-215 10mg, Z-215 20mg, Rabeprazole Sodium
- Where
- Japan
- Volunteers
- 503 people
- Sponsor
- Zeria Pharmaceutical
Gastroesophageal Reflux, Heartburn
HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease
Determine if different levels of acid-suppression with esomeprazole for 6 months on chosen histological markers of esophageal epithelial acid-related disease in patients with upper GI symptoms.
- Conditions
- Gastroesophageal Reflux, Heartburn, Dyspepsia
- Trial name
- NCT00243724
- Testing
- Esomeprazole
- Where
- 10 sites in Canada
- Volunteers
- 350 people
- Sponsor
- AstraZeneca